{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:38:21Z","timestamp":1794339501945,"version":"4.9.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ANR-10-LABX-61"],"award-info":[{"award-number":["ANR-10-LABX-61"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011074","name":"Universit\u00e9 de Lyon","doi-asserted-by":"publisher","award":["ANR-10-LABX-61"],"award-info":[{"award-number":["ANR-10-LABX-61"]}],"id":[{"id":"10.13039\/501100011074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ANR-10-LABX-61"],"award-info":[{"award-number":["ANR-10-LABX-61"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jhep.2021.05.013","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T15:12:41Z","timestamp":1622041961000},"page":"706-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":170,"title":["Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7236-2911","authenticated-orcid":false,"given":"Maria Guadalupe","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-6615","authenticated-orcid":false,"given":"Emmanuel","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5588-5465","authenticated-orcid":false,"given":"Barbara","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-0083","authenticated-orcid":false,"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.05.013_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.08.008","article-title":"Immune-modulators to combat hepatitis B virus infection: from IFN-\u03b1 to novel investigational immunotherapeutic strategies","volume":"122","author":"Isorce","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2021.05.013_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2021.05.013_bib3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"2019 EASL-AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference\u2021","volume":"72","author":"Cornberg","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib4","doi-asserted-by":"crossref","first-page":"21097","DOI":"10.1038\/s41598-020-78001-1","article-title":"Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients","volume":"10","author":"Leboss\u00e9","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2021.05.013_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib6","doi-asserted-by":"crossref","first-page":"100112","DOI":"10.1016\/j.jhepr.2020.100112","article-title":"Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA","volume":"2","author":"Lai","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2021.05.013_bib7","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.05.013_bib8","doi-asserted-by":"crossref","first-page":"a021386","DOI":"10.1101\/cshperspect.a021386","article-title":"Hepadnavirus genome replication and persistence","volume":"5","author":"Hu","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhep.2021.05.013_bib9","doi-asserted-by":"crossref","first-page":"e02007","DOI":"10.1128\/JVI.02007-17","article-title":"Hepatitis B virus DNA integration occurs early in the viral life cycle in an in\u00a0vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles","volume":"92","author":"Tu","year":"2018","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.05.013_bib10","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.3748\/wjg.v20.i30.10238","article-title":"Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma","volume":"20","author":"Ali","year":"2014","journal-title":"WJG"},{"key":"10.1016\/j.jhep.2021.05.013_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2021.05.013_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis\u00a0B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"ELife"},{"key":"10.1016\/j.jhep.2021.05.013_bib13","doi-asserted-by":"crossref","first-page":"E4244","DOI":"10.1073\/pnas.1409986111","article-title":"Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses","volume":"111","author":"K\u00f6niger","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2021.05.013_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128401","article-title":"Does tyrosyl DNA phosphodiesterase-2 play a role in hepatitis B virus genome repair?","volume":"10","author":"Cui","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2021.05.013_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41467-017-00200-8","article-title":"Long-term hepatitis B infection in a scalable hepatic co-culture system","volume":"8","author":"Winer","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2021.05.013_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00922-20","article-title":"Characterization of the termini of cytoplasmic hepatitis B virus deproteinated relaxed circular\u00a0DNA","volume":"95","author":"Cai","year":"2020","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.05.013_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005893","article-title":"DNA polymerase \u03ba is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus","volume":"12","author":"Qi","year":"2016","journal-title":"Plos Pathog"},{"key":"10.1016\/j.jhep.2021.05.013_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007742","article-title":"DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA","volume":"15","author":"Tang","year":"2019","journal-title":"Plos Pathog"},{"key":"10.1016\/j.jhep.2021.05.013_bib19","article-title":"The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation","volume":"13","author":"Long","year":"2017","journal-title":"Plos\u00a0Pathog"},{"key":"10.1016\/j.jhep.2021.05.013_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007124","article-title":"Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus","volume":"14","author":"Kitamura","year":"2018","journal-title":"Plos Pathog"},{"key":"10.1016\/j.jhep.2021.05.013_bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41564-020-0678-0","article-title":"Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation","volume":"5","author":"Wei","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jhep.2021.05.013_bib22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-021-21850-9","article-title":"Hepatitis B virus cccDNA is formed through distinct repair processes of each strand","volume":"12","author":"Wei","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2021.05.013_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF01703079","article-title":"Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell","volume":"8","author":"Bock","year":"1994","journal-title":"Virus Genes"},{"key":"10.1016\/j.jhep.2021.05.013_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/jmbi.2000.4481","article-title":"Structural organization of the hepatitis B virus minichromosome","volume":"307","author":"Bock","year":"2001","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jhep.2021.05.013_bib26","doi-asserted-by":"crossref","first-page":"19975","DOI":"10.1073\/pnas.0908365106","article-title":"Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function","volume":"106","author":"Belloni","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2021.05.013_bib27","doi-asserted-by":"crossref","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","article-title":"Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation","volume":"112","author":"Tropberger","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2021.05.013_bib28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrgastro.2015.152","article-title":"Epigenetic control of HBV by HBx protein\u2014releasing the break?","volume":"12","author":"Protzer","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.cell.2007.01.033","article-title":"The mammalian epigenome","volume":"128","author":"Bernstein","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2021.05.013_bib30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.05.013_bib31","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic therapy against chronic hepatitis B: Hong, Kim, and Guo","volume":"66","author":"Hong","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib32","first-page":"100195","article-title":"De novo synthesis of Hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA","author":"Tu","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2021.05.013_bib33","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","article-title":"Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection","volume":"55","author":"Lucifora","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2015.06.023","article-title":"HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase","volume":"63","author":"Rivi\u00e8re","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib35","doi-asserted-by":"crossref","first-page":"150018","DOI":"10.1098\/rsob.150018","article-title":"Ubiquitylation, neddylation and the DNA damage response","volume":"5","author":"Brown","year":"2015","journal-title":"Open Biol"},{"key":"10.1016\/j.jhep.2021.05.013_bib36","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.celrep.2016.08.026","article-title":"Hepatitis B virus X protein promotes degradation of SMC5\/6 to enhance HBV replication","volume":"16","author":"Murphy","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2021.05.013_bib37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Decorsi\u00e8re","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2021.05.013_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169648","article-title":"The Smc5\/6 complex restricts HBV when localized to ND10 without inducing an innate immune response and is counteracted by the HBV X protein shortly after infection","volume":"12","author":"Niu","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2021.05.013_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2020.01.028","article-title":"Full-length 5\u2019RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum","volume":"73","author":"Stadelmayer","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000321450","article-title":"Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection","volume":"54","author":"Kim","year":"2011","journal-title":"Intervirology"},{"key":"10.1016\/j.jhep.2021.05.013_bib41","article-title":"Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection","volume":"9","author":"Zhang","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2021.05.013_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hep.23611","article-title":"In\u00a0vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice","volume":"52","author":"Lutgehetmann","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1128\/JVI.75.1.311-322.2001","article-title":"Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis","volume":"75","author":"Zhu","year":"2001","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.05.013_bib44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/jhep.2000.8701","article-title":"Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in\u00a0vitro do not lead to reduction of the closed circular DNA","volume":"32","author":"Dandri","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib45","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.21299","article-title":"Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients","volume":"44","author":"Laras","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib46","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1053\/j.gastro.2007.06.057","article-title":"Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients","volume":"133","author":"Volz","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.05.013_bib47","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.05.013_bib48","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Leboss\u00e9","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.26277","article-title":"Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load: Hepatology","volume":"58","author":"Gordon","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib50","doi-asserted-by":"crossref","first-page":"9392","DOI":"10.1128\/jvi.71.12.9392-9399.1997","article-title":"Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus","volume":"71","author":"Moraleda","year":"1997","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.05.013_bib51","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S0618-8278(19)30168-9","article-title":"PS-150-Evidence for the presence of infectious virus in the serum from chronic hepatitis B patients suppressed on nucleos (t)ide therapy with detectable but not quantifiable HBV DNA","volume":"70","author":"Burdette","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib53","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib54","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1128\/JVI.74.3.1495-1505.2000","article-title":"Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections","volume":"74","author":"Guo","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.05.013_bib55","doi-asserted-by":"crossref","first-page":"11652","DOI":"10.1073\/pnas.1635109100","article-title":"Hepatocyte turnover during resolution of a transient hepadnaviral infection","volume":"100","author":"Summers","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jhep.2021.05.013_bib56","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1073\/pnas.0409332102","article-title":"Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection","volume":"102","author":"Mason","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jhep.2021.05.013_bib57","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jhep.2021.05.013_bib58","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1073\/pnas.0308478100","article-title":"Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2021.05.013_bib59","doi-asserted-by":"crossref","first-page":"17780","DOI":"10.1073\/pnas.0508913102","article-title":"Dynamics of hepatitis B virus clearance in chimpanzees","volume":"102","author":"Murray","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jhep.2021.05.013_bib60","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in\u00a0vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.05.013_bib61","article-title":"Distribution of hepatitis B virus nuclear DNA","volume":"92","author":"Li","year":"2017","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.05.013_bib62","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.1128\/JVI.76.12.6356-6363.2002","article-title":"Half-life of the duck hepatitis B virus covalently closed circular DNA pool in\u00a0vivo following inhibition of viral replication","volume":"76","author":"Addison","year":"2002","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.05.013_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jtbi.2014.11.020","article-title":"In silico single cell dynamics of hepatitis B virus infection and clearance","volume":"366","author":"Murray","year":"2015","journal-title":"J\u00a0Theor Biol"},{"key":"10.1016\/j.jhep.2021.05.013_bib64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtbi.2018.06.020","article-title":"The dynamics of integration, viral suppression and cell-cell transmission in the development of occult Hepatitis B virus infection","volume":"455","author":"Goyal","year":"2018","journal-title":"J\u00a0Theor Biol"},{"key":"10.1016\/j.jhep.2021.05.013_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161978","article-title":"Modelling the impact of cell-to-cell transmission in hepatitis B virus","volume":"11","author":"Goyal","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2021.05.013_bib66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coisb.2019.10.003","article-title":"Within-host mathematical models of hepatitis B virus infection: past, present, and future","volume":"18","author":"Goyal","year":"2019","journal-title":"Curr Opin Syst Biol"},{"key":"10.1016\/j.jhep.2021.05.013_bib67","doi-asserted-by":"crossref","first-page":"104553","DOI":"10.1016\/j.antiviral.2019.104553","article-title":"Non-invasive biomarkers for chronic hepatitis B virus infection management","volume":"169","author":"Charre","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2021.05.013_bib68","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2021.05.013_bib69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2016.08.026","article-title":"Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA","volume":"134","author":"Liu","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2021.05.013_bib70","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S0618-8278(19)30086-6","article-title":"PS-074-A first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and HBV DNA suppression in the HBV circle mouse model through elimination of cccDNA-like molecules in the mouse liver","volume":"70","author":"Wang","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib71","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2010.20","article-title":"Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs","volume":"18","author":"Cradick","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2021.05.013_bib72","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in\u00a0vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2021.05.013_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2020.04.019","article-title":"2020 ASGCT annual meeting abstracts","volume":"28","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2021.05.013_bib74","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A\u00a0programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jhep.2021.05.013_bib75","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jhep.2021.05.013_bib76","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/d41586-020-02765-9","article-title":"Pioneers of revolutionary CRISPR gene editing win chemistry Nobel","volume":"586","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2021.05.013_bib77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/genes9040207","article-title":"Gene therapy for chronic HBV\u2014can we eliminate cccDNA?","volume":"9","author":"Bloom","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.jhep.2021.05.013_bib78","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.copbio.2018.07.005","article-title":"The influence of eukaryotic chromatin state on CRISPR\u2013Cas9 editing efficiencies","volume":"55","author":"Verkuijl","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.jhep.2021.05.013_bib79","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13450","article-title":"Nucleosome breathing and remodeling constrain CRISPR-Cas9 function","volume":"5","author":"Isaac","year":"2016","journal-title":"ELife"},{"key":"10.1016\/j.jhep.2021.05.013_bib80","doi-asserted-by":"crossref","first-page":"S841","DOI":"10.1016\/S0168-8278(20)32126-7","article-title":"SAT376 - targeting hepatitis B virus with CRISPR\/Cas9 approach","volume":"73","author":"Martinez","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib81","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","article-title":"CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice","volume":"20","author":"Stone","year":"2021","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"10.1016\/j.jhep.2021.05.013_bib82","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"10.1016\/j.jhep.2021.05.013_bib83","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2021.05.013_bib84","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2021.05.013_bib85","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/crispr.2018.0037","article-title":"Engineering CRISPR-Cas9 RNA\u2013protein complexes for improved function and delivery","volume":"1","author":"Rouet","year":"2018","journal-title":"CRISPR J"},{"key":"10.1016\/j.jhep.2021.05.013_bib86","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2021.05.013_bib87","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jhep.2021.05.013_bib88","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2021.05.013_bib89","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent inactivation of HBV genomes by CRISPR\/Cas9-Mediated non-cleavage base editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol Ther - Nucleic Acids"},{"key":"10.1016\/j.jhep.2021.05.013_bib90","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41467-020-15887-5","article-title":"Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity","volume":"11","author":"Yu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2021.05.013_bib91","doi-asserted-by":"crossref","first-page":"30812","DOI":"10.1074\/jbc.M112.393181","article-title":"Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A","volume":"287","author":"Love","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2021.05.013_bib92","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nsmb.1744","article-title":"APOBEC3 proteins mediate the clearance of foreign DNA from human cells","volume":"17","author":"Stenglein","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jhep.2021.05.013_bib93","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhep.2021.05.013_bib94","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02190-17","article-title":"Asymmetric modification of hepatitis B virus (HBV) genomes by an endogenous cytidine deaminase inside HBV cores informs a model of reverse transcription","volume":"92","author":"Nair","year":"2018","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.05.013_bib95","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib96","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1008354","article-title":"T\u00a0cell receptor-therapy in HBV-related hepatocellularcarcinoma","volume":"4","author":"Bertoletti","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jhep.2021.05.013_bib97","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.03.027","article-title":"Nonlytic lymphocytes engineered to express virus-specific T-cell receptors limit HBV infection by activating APOBEC3","volume":"155","author":"Koh","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.05.013_bib98","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1073\/pnas.0408223102","article-title":"Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in\u00a0vitro and in\u00a0vivo","volume":"102","author":"Suspene","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jhep.2021.05.013_bib99","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/mt.2016.94","article-title":"Complete spectrum of CRISPR\/Cas9-induced mutations on HBV cccDNA","volume":"24","author":"Seeger","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2021.05.013_bib100","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","article-title":"Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers","volume":"33","author":"Hilton","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2021.05.013_bib101","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2021.05.013_bib102","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/hep.23011","article-title":"Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain","volume":"50","author":"Gao","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib103","article-title":"IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome","volume":"10","author":"Palumbo","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2021.05.013_bib104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2016.03.008","article-title":"Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus","volume":"130","author":"Isorce","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2021.05.013_bib105","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.4049\/jimmunol.171.9.4708","article-title":"IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma cell line Hep3B","volume":"171","author":"Lin","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2021.05.013_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030360","article-title":"Transforming growth factor-\u03b21 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4\u03b1 expression","volume":"7","author":"Hong","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2021.05.013_bib107","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.antiviral.2018.08.014","article-title":"Host functions used by hepatitis B virus to complete its life cycle: implications for developing host-targeting agents to treat chronic hepatitis B","volume":"158","author":"Mitra","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2021.05.013_bib108","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.7150\/ijms.26125","article-title":"AGK2, A SIRT2 inhibitor, inhibits hepatitis B virus replication in\u00a0vitro and in\u00a0vivo","volume":"15","author":"Yu","year":"2018","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jhep.2021.05.013_bib109","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/S0168-8278(17)31855-X","article-title":"Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model","volume":"66","author":"Gilmore","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib110","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.29133","article-title":"PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation","volume":"66","author":"Zhang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib111","doi-asserted-by":"crossref","first-page":"100167","DOI":"10.1016\/j.jhepr.2020.100167","article-title":"Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg","volume":"2","author":"Fern\u00e1ndez-Barrena","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2021.05.013_bib112","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00248-19","article-title":"Spatiotemporal analysis of hepatitis B virus X protein in primary human hepatocytes","volume":"93","author":"Kornyeyev","year":"2019","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2021.05.013_bib113","article-title":"Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5\/6 complex and silencing of the viral genome in\u00a0vivo","author":"Allweiss","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.05.013_bib114","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1134\/S0006297914020047","article-title":"Hepatitis B virus can be inhibited by DNA methyltransferase 3a via specific zinc-finger-induced methylation of the X promoter","volume":"79","author":"Xirong","year":"2014","journal-title":"Biochem Mosc"},{"key":"10.1016\/j.jhep.2021.05.013_bib115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcmgh.2018.10.010","article-title":"Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx\u2013DDB1 interaction","volume":"7","author":"Sekiba","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib116","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/hep.30491","article-title":"Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8\u2013activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus","volume":"69","author":"Sekiba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib117","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2021.05.013_bib118","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/S0168-8278(20)30790-X","article-title":"Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study","volume":"73","author":"Yuen","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib119","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0168-8278(20)30597-3","article-title":"Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment","volume":"73","author":"Gane","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib120","doi-asserted-by":"crossref","first-page":"1A","DOI":"10.1002\/hep.31578","article-title":"Oral abstracts","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib121","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0168-8278(20)30646-2","article-title":"Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with isis 505358 in chronic hepatitis B (CHB) patients on stable nucleos (t)ide analogue (NA) regimen and in NA-naive CHB patients: phase 2a, randomized, double-blind, placebo-controlled study","volume":"73","author":"Yuen","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib122","first-page":"1489A","article-title":"First clinical experience with RNA interference-based triple combination therapy in chronic hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos (t) ide analogue","volume":"70","author":"Yuen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.013_bib123","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30651-6","article-title":"48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV\/HDV co-infection","volume":"73","author":"Wedemeyer","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib124","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir\u00a0disoproxil, and pegylated interferon alfa-2a in patients with\u00a0chronic HBV infection na\u00efve to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.05.013_bib125","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30650-4","article-title":"Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study","volume":"73","author":"Gane","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib126","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.05.013_bib127","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic\u00a0vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","article-title":"Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand","volume":"3","author":"Maini","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.05.013_bib129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00281-020-00780-6","article-title":"Epigenetic modulation in chronic hepatitis B virus infection","volume":"42","author":"Dandri","year":"2020","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jhep.2021.05.013_bib130","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A\u00a0global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821003482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821003482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T08:56:26Z","timestamp":1736585786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821003482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0168827821003482"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.05.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}